Aug 2026· Translational Research: The Journal of Laboratory and Clinical Medicine· 0 citations· 195 references
Medicine
TL;DR
This review traces the historical evolution of regenerative therapies for NDDs - from early exploratory cell transplantation to modern approaches involving pluripotent stem cells (PSCs) and in vivo direct reprogramming and elucidate the core strategies of regenerative medicine within an integrated framework encompassing "Replacement", "Regeneration", and "Rejuvenation".
Abstract
In the context of global ageing, the prevalence of neurodegenerative diseases (NDDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), is rapidly increasing. However, current symptomatic treatments have achieved limited benefits in clinical settings and fundamentally fail to reverse the progressive loss of specific neuronal populations. Halting neurodegeneration and restoring impaired cognitive, motor or visual functions through nerve regeneration and circuit reconstruction represent the clinically meaningful goals for treatments of NDDs. Regenerative medicine has emerged as a promising paradigm to address this unmet need. In this review, we trace the historical evolution of regenerative therapies for NDDs - from early exploratory cell transplantation to modern approaches involving pluripotent stem cells (PSCs) and in vivo direct reprogramming. Furthermore, we elucidate the core strategies of regenerative medicine within an integrated framework encompassing "Replacement", "Regeneration", and "Rejuvenation". Finally, we highlight recent advances in clinical research, particularly milestone trials in cell replacement therapy for PD, as well as the application of mesenchymal stem cells (MSCs) in AD and ALS.
This review critically discusses current developments, ongoing clinical trials, therapeutic mechanisms, and key challenges associated with stem cell-based interventions, and translational barriers that must be addressed for the successful clinical implementation of stem cell therapies in neurodegenerative diseases.
Sujatha Krishnamoorthy, Vibhusha Venkatesan, Urbi Roy· Journal of Sustainable Chemi...· 0 citations
Stem cell therapy, leveraging self-renewal, multi-directional differentiation and paracrine regulation, has become a research hotspot in the field of PD treatment, bringing new hope for the radical cure of PD.
Lian-Cheng Zhi· Journal of Clinical Technolo...· 0 citations
This work incorporates disease-specific mitochondrial pathology with current progress in targeted nanotherapeutics, age-associated delivery barriers, clinical revolution, and emerging artificial intelligence (AI)-enabled precision therapeutic approaches to improve therapeutic outcomes in aging-associated neurodegenerat...
Dnyandev G. Gadhave, Ashish B. Jadhav, Nitin Waghamode et al.· Advanced Healthcare Material...· 2 citations
These findings advocate for a paradigm shift from a neuron-centric to a glia-inclusive framework in PD research and treatment, positioning astrocytes as central players in the quest for disease-modifying therapies.
Shuang Wu, Wenjun Wang, Lin-Li Yang et al.· Experimental Neurology· 0 citations
Amyotrophic Lateral Sclerosis (ALS) is caused by progressive degeneration of upper and lower motor neurons. The disease is late onset, and to date, no early diagnosis is possible. Patients with ALS have a 5-year survival rate since diagnosis. Though recent studies highlighted the possible mechanisms of motor neuron deg...
Trisha Raghunathan, B. Parthasarathy, P. Prabhu et al.· Discover Nano· 0 citations
The urgent need for reliable biomarkers, early diagnosis, and multidisciplinary disease-modifying strategies for future therapeutic interventions is highlighted, with particular emphasis on challenges associated with bench-to-bedside translation.
Jeewanjot Singh, Subhi Sharma, Prabhjot Singh et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.